Department of Nephrology, Odense University Hospital, 5000, Odense C, Denmark.
Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark.
BMC Nephrol. 2019 Aug 7;20(1):307. doi: 10.1186/s12882-019-1469-9.
Atypical hemolytic uremic syndrome (aHUS) is a disorder of the microvasculature with hemolytic anemia, thrombocytopenia and acute kidney injury. Nowadays, aHUS is successfully treated with eculizumab, a humanized, chimeric IgG2/4 kappa antibody, which binds human complement C5 and blocks generation of C5a and membrane-attack-complex.
A 25-year-old woman with end stage renal disease due to relapsing atypical hemolytic uremic syndrome had a relapse of the disease during pregnancy. She was treated with eculizumab. We measured reduced formation of the membrane-attack complex in newborn's umbilical cord vein blood using the sensitive and specific Palarasah-Nielsen-ELISA.
Eculizumab treatment of the mother with end stage renal disease may cause reduced innate immunity which could render newborns more susceptible to infections.
非典型溶血性尿毒症综合征（aHUS）是一种微血管疾病，伴有溶血性贫血、血小板减少和急性肾损伤。如今，aHUS 可以通过依库珠单抗成功治疗，这是一种人源化、嵌合 IgG2/4 kappa 抗体，可结合人补体 C5，阻止 C5a 和膜攻击复合物的生成。
一位 25 岁女性因反复发作的非典型溶血性尿毒症综合征导致终末期肾病，在怀孕期间疾病复发。她接受了依库珠单抗治疗。我们使用敏感且特异的 Palarasah-Nielsen-ELISA 测量新生儿脐静脉血中膜攻击复合物形成减少的情况。
患有终末期肾病的母亲接受依库珠单抗治疗可能导致先天免疫能力降低，使新生儿更容易感染。
